FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to nucleic acid encoding recombinant immunoglobulin (Ig) containing only a heavy chain that contains one or several V gene segments of a human, one or several D gene segments of a human, and one or several J gene segments of a human, while at least one of the specified J-segments of a human contains codon encoding another amino acid residue in comparison with a native amino acid residue in the first position of the fourth frame region (FR4) that is capable of violating the integrity of a hydrophobic stain exposed on the surface. A transgenic animal containing the above-mentioned nucleic acid is also disclosed.
EFFECT: invention is effective for producing an antibody containing only a heavy chain (HCAb).
32 cl, 7 dwg, 1 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST ANG-2 CONTAINING ONLY HEAVY CHAIN | 2016 |
|
RU2749674C2 |
| HEAVY CHAIN-ONLY ANTIBODIES THAT BIND TO CD19 | 2019 |
|
RU2824170C2 |
| BCMA HEAVY CHAIN ANTIBODIES | 2018 |
|
RU2816994C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTIBODIES CONTAINING ONLY HEAVY CHAINS THAT BIND TO CD22 | 2018 |
|
RU2797348C2 |
| ANTIBODIES FOR TREATMENT OF HEPATITIS B INFECTION AND RELATED DISEASES | 2018 |
|
RU2765878C2 |
| ANTI-CD112R ANTIBODY COMPOSITIONS AND RELATED METHODS | 2019 |
|
RU2819624C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| CD3 BINDING ANTIBODIES | 2017 |
|
RU2807216C2 |
